Cambridge Epigenetix TrueMethyl™ Beta Trial

Cambridge Epigenetix (CEGX) has developed the TrueMethyl™ kit and workflow, a product with unrivalled accuracy and simplicity for base specific, quantitative detection of cytosine methylation (5mC) and hydroxymethylation (5hmC). As a key step in the product development process, the TrueMethyl™ kit has been subjected to a highly successful and rigorous beta trial test involving 13 leading epigenetics labs in USA, Europe and Japan. This application note describes the design of the beta trial and summarises the key results, demonstrating the utility of the technique in the quantitative and base-specific detection and discrimination of cytosine, 5mC and 5hmC.